Accessing the Latest Advancements

There is a way to be among the first to access new NET therapies. You can participate in a clinical trial. Listen to this new NETWise podcast to learn what factors you should consider before agreeing to participate in a study. We talk with NET specialists like Drs. Satya Das, Daniel Halperin, Renuka Iyer, Pam Kunz, Nitya Raj, and Diane Reidy-Lagunes to learn what questions to ask your care team when considering a clinical trial. (MORE)

You Told Us What You Wanted to See in Our Virtual Conference

What are the most pressing concerns of neuroendocrine cancer patients and family members right now? That's what we asked in an online survey last month. The answers will shape the topics addressed in our upcoming October 10th virtual conference. Mark your calendar and learn what the survey said. (MORE)

15-Year NET Survivor Offers Advice

Brian Bowe has survived more than stage IV neuroendocrine cancer. He was the Executive Director of the Gilroy Garlic Festival when a gunman killed 3 people and wounded 17 one year ago. He's made major changes in his life to find improved health and balance. Looking back, he points to one step in his journey that helped him take control of his health—participating in a NET support group. (MORE)

Coming Soon

Primary Site-Specific Podcasts

Starting next month, we'll launch a series of NETWise podcasts exploring tumors by primary site. Check out the NET specialists we're lining up to help us with this deep dive into NETs. (MORE)

The Term "Carcinoid" Is So 1907

Theodore Roosevelt was president. Oklahoma became a state. And a German pathologist looked into a microscope and described something that looked "cancer-like" as carcinoid. See why many say the term carcinoid cancer should be replaced by neuroendocrine cancer to increase awareness and understanding of this uncommon cancer. (MORE)

Cancer & COVID-19

On July 17, 2020, the U.S. Centers for Disease Control (CDC) revised the list of medical conditions associated with an increased risk for severe illness from COVID-19 to include cancer. According to the CDC, we don't yet know what types of cancer or stages of disease are most likely to cause complications. To understand your potential risk for COVID-19 complications, talk to your doctor. (MORE)

Inherited Risk Factors for NETs

Can the risk for neuroendocrine cancer be passed down from parents to children? Can genetic testing help inform a treatment plan? Who should get genetic testing? Learn about the role of genetics in neuroendocrine tumors and associated syndromes in this 24-minute talk by Lauren Fishbein, MD, PhD, University of Colorado. (MORE)

Scholarship for those with Rare Diseases

The EveryLife Foundation for Rare Diseases offers the #RAREis Scholarship Fund to enrich the lives of adults living with rare diseases. Apply for a one-time award of $5,000 for the Spring 2021 semester by August 28, 2020, at 3:00 PM CST. (MORE)

Exploring a New Subtype of Lung NETs

A NETRF-funded researcher in France is exploring a lung supra-carcinoid, which has the biological structure of a neuroendocrine tumor with molecular and clinical features of large cell neuroendocrine carcinoma. Dr. Lynnette Fernandez-Cuesta's work may help us understand the links between low- and high-grade lung neuroendocrine tumors. (MORE)

Remembering Makes a Difference

NETRF is shining a light on its Everlasting Impact Tribute program, which helps families make a larger impact on NET research with a dynamic program to honor their loved ones. (MORE)

Addressing Equity and Anti-racism

The Neuroendocrine Tumor Research Foundation’s (NETRF) mission is to find treatments and ultimately a cure for the thousands of patients living with neuroendocrine cancer. As an organization dedicated to funding research and educating patients, inclusion and equity are essential core values for NETRF. With the attention brought to racial injustice and other forms of inequality at this unique moment in history, NETRF joins others in the cancer community to speak out in support of anti-racism. Read our statement here.

This issue of NETRF's eUpdate has been sponsored in part by:

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

31 St. James Avenue, Suite 365
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.